Astellas has expansive coverage of the Asia & Oceania region. We currently  have 10 sales subsidiaries in this region, following the establishment of a  sales subsidiary in Singapore in July 2013. By working to maximize the value of our products, primarily through new  drugs sold globally, we are aiming to sustain a high level of growth. In the course of expanding our business, we remain constantly mindful of  the latest developments surrounding the different intellectual property and  healthcare systems of each country. We are also working hard to recruit tal- ented human resources and further increase the motivation of employees by  improving our corporate culture. China remains the driving force behind our high growth, supported by the  efforts of about 760 MRs. In this manner, we are continuously increasing our  sales force in the Asia & Oceania region. At the same time, we are working to  upgrade our management systems, including compliance. Masatoshi Kuroda Senior Vice President and President, Asia/Oceania Business Review of Operations (¥ billion) 2013.3 J-GAAP 2014.3 2015.3 (Forecast) IFRS J-GAAP IFRS Sales in Asia & Oceania 42.9 $_{⬆}$ 58.0 58.0 $_{⬆}$ 68.7 Immunosuppressant Prograf 18.9 $_{⬆}$ 25.0 25.0 $_{⬆}$ 29.2 Treatment for the functional symptoms associated with benign prostatic hyperplasia Harnal 10.9 $_{⬆}$ 14.9 14.9 $_{⬆}$ 16.8 OAB treatment Vesicare 3.0 $_{⬆}$ 3.8 3.8 $_{⬆}$ 4.8 Candin-type antifungal agent MYCAMINE 2.3 $_{⬆}$ 3.4 3.4 $_{⬆}$ 4.4 Treatment for atopic dermatitis Protopic 1.7 $_{⬆}$ 2.6 2.6 $_{⬆}$ 3.6 Sales of Major Products Continuous Product Introductions (Approvals and Launches) (2013.4–2014.6) South Korea Launch of XTANDI Indonesia Launch of Prograf XL Thailand Launch of Eligard Vietnam Approval of Eligard Hong Kong Approval of BETMIGA Australia Approval of MYCAMINE Hong Kong Launch of Eligard Malaysia Approval of MYCAMINE 2013 May November June December August October Singapore Approval of  MYCAMINE South Korea Approval of  BETMIGA May Malaysia Approval of Eligard Taiwan Approval of Eligard Philippines Approval of Advagraf Australia Approval of XTANDI Singapore Launch of MYCAMINE June Hong Kong Launch of  BETMIGA Singapore Approval of Eligard Taiwan Approval of BETMIGA Australia Launch of BETMIGA March April February 2014 Annual Report 2014 _  Astellas Pharma Inc.  51